How did IMCIVREE help reduce measures of weight and hunger in the POMC or PCSK1 and LEPR trials?

← Swipe left or right to see all tabs →

In clinical studies, IMCIVREE reduced weight and hunger for people with obesity due to POMC or PCSK1 deficiency

WEIGHT

STUDY 1

People with obesity due to POMC or PCSK1 deficiency

POMC/PCSK1 weight data

8 out of 10 people lost at least 10% of
their body weight at 1 year

POMC/PCSK1 study weight chart

*Participants who experienced weight loss of 5 kg/11 lb (or 5% if their starting
weight was less than 100 kg/220 lb) during the first 10 weeks.

HUNGER

STUDY 1

People with obesity due to POMC or PCSK1 deficiency

Decrease in hunger

After 1 year, participants (n=8)
experienced a decrease from 7.9 to 5.5
in the median daily hunger score.

Changes in hunger were evaluated using a questionnaire that was completed each day for 1 year, by participants who were 12 years of age or older. The questionnaire measured hunger using a score ranging from 0 ("not hungry at all") to 10 ("hungriest possible").

A median is the middle value of a set of data that have been put into numerical order. The median is the value that divides the data into 2 halves.

Impact of stopping treatment

Treatment was stopped for a period of time to see how it impacted weight and hunger.

Over this withdrawal period:

  • Weight increased; when the withdrawal period ended and treatment was restarted, weight loss continued
  • Hunger scores generally worsened; hunger scores improved once treatment was restarted

In clinical studies, IMCIVREE reduced weight and hunger for people with obesity due to LEPR deficiency

WEIGHT

STUDY 2

People with obesity due to LEPR deficiency

LEPR weight loss data

5 out of 11 people lost at least 10% of their body weight at 1 year

LEPR study weight chart

*Participants who experienced weight loss of 5 kg/11 lb (or 5% if their starting
weight was less than 100 kg/220 lb) during the first 10 weeks.

HUNGER

STUDY 2

People with obesity due to LEPR deficiency

Reduce hunger

After 1 year, participants (n=8) experienced a decrease from 7.0 to 4.4 in the median daily hunger score.

Changes in hunger were evaluated using a questionnaire that was completed each day for 1 year, by participants who were 12 years of age or older. The questionnaire measured hunger using a score ranging from 0 ("not hungry at all") to 10 ("hungriest possible").

A median is the middle value of a set of data that have been put into numerical order. The median is the value that divides the data into 2 halves.

Impact of stopping treatment

Treatment was stopped for a period of time to see how it impacted weight and hunger.

Over this withdrawal period:

  • Weight increased; when the withdrawal period ended and treatment was restarted, weight loss continued
  • Hunger scores generally worsened; hunger scores improved once treatment was restarted

A lot has changed, and when I look at the hunger today, I’m assuming it’s on the same level as other people.

— Person who is living with POMC deficiency

I’m very satisfied I’ve lost a lot of weight, and I have a lot more energy. It’s nice to see that someone is paying attention to this, and there’s a medication for this, that they’re deploying people to deal with this problem, when people used to have to go without care.

— Person who is living with POMC deficiency

Now, I really feel it. My stomach growls and I notice that I am hungry. Experiencing both fullness and hunger is something I have never felt before. It's funny.

— Person who is living with LEPR deficiency

Important Safety Information

What is IMCIVREE?

IMCIVREE is a prescription medicine used in adults and children 6 years of age and older with obesity due to the genetic conditions pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency, to help them lose weight and keep the weight off.

Your healthcare provider should order an FDA-approved test to confirm POMC, PCSK1, or LEPR deficiency before you start using IMCIVREE.

IMCIVREE is not for use in people with the following conditions because it may not work:

  • Obesity due to suspected POMC, PCSK1, or LEPR deficiency not confirmed by genetic testing or with benign or likely benign genetic testing results
  • Other types of obesity not related to POMC, PCSK1, or LEPR deficiency, or other FDA-approved uses of IMCIVREE, including obesity associated with other genetic conditions and general obesity

It is not known if IMCIVREE is safe and effective in children under 6 years of age.

Before you use IMCIVREE, tell your healthcare provider about all your medical conditions, including if you:

  • Have or have had areas of darkened skin, including skin discoloration (hyperpigmentation)
  • Have or have had depression, or suicidal thoughts or behavior
  • Have kidney problems
  • Are pregnant or planning to become pregnant. Losing weight while pregnant may harm your unborn baby. Your healthcare provider may stop your treatment with IMCIVREE if you become pregnant. Tell your healthcare provider if you become pregnant or think you might be pregnant during treatment with IMCIVREE
  • Are breastfeeding or plan to breastfeed. It is not known if IMCIVREE passes into your breast milk. You should not breastfeed during treatment with IMCIVREE

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

See the detailed Instructions for Use that come with your IMCIVREE to learn how to prepare and inject IMCIVREE, and how to properly throw away (dispose of) used syringes and needles.

What are the possible side effects of IMCIVREE?

IMCIVREE may cause serious side effects, including:

  • Male and female sexual function problems. IMCIVREE can cause an erection that happens without any sexual activity in males (spontaneous penile erection) and unwanted sexual reactions (changes in sexual arousal that happen without any sexual activity) in females. If you have an erection lasting longer than 4 hours, get emergency medical help right away
  • Depression and suicidal thoughts or actions. You or a caregiver should call your healthcare provider right away if you have any new or worsening symptoms of depression, suicidal thoughts or behaviors, or any unusual changes in mood or behavior
  • Increased skin pigmentation and darkening of skin lesions (moles or nevi) you already have. These changes happen because of how IMCIVREE works in the body and will go away when you stop using IMCIVREE. You should have a full body skin exam before starting and during treatment with IMCIVREE to check for skin changes
  • Benzyl alcohol toxicity. Benzyl alcohol is a preservative in IMCIVREE. Benzyl alcohol can cause serious side effects, including death, in premature and low-birth weight infants who have received medicines that contain benzyl alcohol. IMCIVREE should not be used in premature and low-birth weight infants

The most common side effects of IMCIVREE include darkening of the skin, injection site reactions, nausea, headache, diarrhea, stomach pain, vomiting, depression, and an erection that happens without any sexual activity in males.

These are not all the possible side effects of IMCIVREE. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or to Rhythm Pharmaceuticals at 1-833-789-6337.

Please see the full Patient Information for additional Safety Information.

Important Safety Information

What is IMCIVREE?

IMCIVREE is a prescription medicine used in adults and children 6 years of age and older with obesity due to the genetic conditions pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency, to help them lose weight and keep the weight off.

Your healthcare provider should order an FDA-approved test to confirm POMC, PCSK1, or LEPR deficiency before you start using IMCIVREE.

IMCIVREE is not for use in people with the following conditions because it may not work:

  • Obesity due to suspected POMC, PCSK1, or LEPR deficiency not confirmed by genetic testing or with benign or likely benign genetic testing results
  • Other types of obesity not related to POMC, PCSK1, or LEPR deficiency, or other FDA-approved uses of IMCIVREE, including obesity associated with other genetic conditions and general obesity

It is not known if IMCIVREE is safe and effective in children under 6 years of age.

Before you use IMCIVREE, tell your healthcare provider about all your medical conditions, including if you:

  • Have or have had areas of darkened skin, including skin discoloration (hyperpigmentation)
  • Have or have had depression, or suicidal thoughts or behavior
  • Have kidney problems
  • Are pregnant or planning to become pregnant. Losing weight while pregnant may harm your unborn baby. Your healthcare provider may stop your treatment with IMCIVREE if you become pregnant. Tell your healthcare provider if you become pregnant or think you might be pregnant during treatment with IMCIVREE
  • Are breastfeeding or plan to breastfeed. It is not known if IMCIVREE passes into your breast milk. You should not breastfeed during treatment with IMCIVREE

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

See the detailed Instructions for Use that come with your IMCIVREE to learn how to prepare and inject IMCIVREE, and how to properly throw away (dispose of) used syringes and needles.

What are the possible side effects of IMCIVREE?

IMCIVREE may cause serious side effects, including:

  • Male and female sexual function problems. IMCIVREE can cause an erection that happens without any sexual activity in males (spontaneous penile erection) and unwanted sexual reactions (changes in sexual arousal that happen without any sexual activity) in females. If you have an erection lasting longer than 4 hours, get emergency medical help right away
  • Depression and suicidal thoughts or actions. You or a caregiver should call your healthcare provider right away if you have any new or worsening symptoms of depression, suicidal thoughts or behaviors, or any unusual changes in mood or behavior
  • Increased skin pigmentation and darkening of skin lesions (moles or nevi) you already have. These changes happen because of how IMCIVREE works in the body and will go away when you stop using IMCIVREE. You should have a full body skin exam before starting and during treatment with IMCIVREE to check for skin changes
  • Benzyl alcohol toxicity. Benzyl alcohol is a preservative in IMCIVREE. Benzyl alcohol can cause serious side effects, including death, in premature and low-birth weight infants who have received medicines that contain benzyl alcohol. IMCIVREE should not be used in premature and low-birth weight infants

The most common side effects of IMCIVREE include darkening of the skin, injection site reactions, nausea, headache, diarrhea, stomach pain, vomiting, depression, and an erection that happens without any sexual activity in males.

These are not all the possible side effects of IMCIVREE. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or to Rhythm Pharmaceuticals at 1-833-789-6337.

Please see the full Patient Information for additional Safety Information.